1 published article · Updated continuously
34 trials tracked for Dengue fever: 10 in phase 3 or 4 and 9 with published results. The most-cited published study has 1091 citations.
Showing the 34 most-cited and recently-updated of 34 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Multiple phase 3 trials of the live attenuated tetravalent dengue vaccine CYD-TDV (CYD dengue vaccine) demonstrated immunogenicity against all four dengue serotypes. In a large efficacy trial (N=20,869), the vaccine reduced symptomatic virologically confirmed dengue cases compared to placebo (273 vs 380 cases) 1. Another large trial (N=10,275) also reported fewer symptomatic cases after dose 1 (276 vs 302) and after dose 2 (205 vs 238) 10. Seropositivity rates (antibody titers ≥10 1/dil) against each serotype were high after vaccination, ranging from about 72% to 95% in one trial 1 and 52% to 94% in another 10.
The Takeda tetravalent dengue vaccine (TDV/TAK-003) also induced seropositivity against all four serotypes in phase 3 trials. In one trial (N=200), seropositivity rates at day 120 and 270 were ≥97% for each serotype 3. In another (N=923), seropositivity rates at day 120 were 96.9–99.2% for serotypes 1–4, with lower baseline rates (1.7–6.7%) 5. Booster doses maintained neutralizing antibody titers at 6 months post-booster, with geometric mean titers (GMTs) ranging from 23.5 to 553.9 across serotypes in different parent trials 7.
Reactogenicity was generally mild to moderate. In a phase 3 trial of CYD-TDV (N=250), solicited injection-site and systemic reactions occurred in 69.3% and 56.9% of participants, respectively, with severe reactions rare (1.0% and 0.0%) 2. For TDV, solicited local reactions were reported in 35.9% after the first dose, with severe reactions in 0.5–3.6% 3. Systemic reactions after TDV were reported in 34.7–43.3% across doses, with severe events in 22.5–28.9% 5. In a pediatric trial (N=1050), seropositivity rates after vaccination were high (77.8–97.2%) 13.
CYD-TDV was also studied for co-administration with HPV vaccines. In dengue-seropositive participants, co-administration with Cervarix or Gardasil did not impair immune responses to either vaccine; GMTs against HPV antigens were comparable to placebo, and dengue serotype GMTs were maintained 69. A trial with the 9-valent HPV vaccine (N=614) showed 100% seropositivity for all HPV types and dengue serotypes after co-administration 8.
AI synthesis of 14 cited trials, updated Aug 28, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
